200.00% intraday jump: MDQK.HM stock shows thin liquidity 12 Feb 2026

MDQK.HM stock jumped 200.00% intraday to €7.50 on 12 Feb 2026 during market hours on the HAM exchange in Germany. The move came on thin volume — 35.00 shares traded versus an average of 41.00. There is no public earnings release or formal company news timed to this spike. Investors should treat the rally as a high-volume-movers event driven by liquidity and microcap dynamics.

MDQK.HM stock market move and intraday data

MediNavi AG (MDQK.HM) opened at €2.50 and reached a day high of €7.50, matching the year high on 12 Feb 2026. The recorded change was €5.00 or 200.00% versus the previous close of €2.50. Volume was 35.00 against an average daily volume of 41.00, showing the move happened on low absolute liquidity.

This pattern is common in small-cap listings where few shares trade. With reported market cap data blank, the price swing likely reflects order imbalances rather than broad market revaluation.

Trading, liquidity and technical snapshot

The technical picture shows a sharp gap above the 50-day average €2.50 and the 200-day average €2.00, both far below the intraday peak. ATR is 5.00, signalling high intraday volatility. Relative volume of 0.85 (35.00/41.00) confirms activity was not large by historic standards.

Traders should note on-chain indicators are limited. Lack of RSI and MACD values suggests unreliable trend signals at current data granularity. For active traders, the priority is monitoring order book depth and any regulatory filings on the HAM exchange.

Fundamentals, valuation and financial metrics

Public financial metrics for MediNavi AG show limited operating data. EPS and P/E are listed as null. Key ratios report a current ratio 41.50 and cash ratio 38.27, reflecting reported working capital cushions. Enterprise value is negative -255031.00, which indicates dataset oddities or large cash versus liabilities in reported figures.

These figures imply a thin operational footprint and limited revenue-per-share disclosures. Without an earnings announcement, valuation relies on asset-level measures and any near-term corporate developments.

Meyka AI stock grade and technical analysis for MDQK.HM stock

Meyka AI rates MDQK.HM with a score of 62.59 out of 100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Technical indicators are mixed: ATR 5.00 indicates volatility, while moving averages show the current price well above short- and long-term averages. Investors should view the grade as model-based context, not investment advice.

Sector context and how healthcare trends matter

MediNavi AG sits in the Healthcare sector and the Medical – Healthcare Information Services industry. The broader healthcare sector performance shows modest near-term moves and a 1Y performance near -2.70%, so MDQK.HM’s spike is idiosyncratic rather than sector-driven. Average healthcare volume is 89,894.00, far larger than MDQK.HM’s turnover.

Analyst consensus points to opportunities in digital health platforms, but MediNavi’s public disclosures remain limited. Any material business update or partnership would be a genuine catalyst for sustained price discovery.

Risks, catalysts and short-term trading strategy

Primary risk is extreme illiquidity: low daily volume amplifies price moves and widens bid-ask spreads. Secondary risks include sparse disclosures and no scheduled earnings announcement. Catalysts that could justify sustained gains are a confirmed corporate update, regulatory filing on HAM, or a material partnership.

For high-volume-movers strategy, traders should size positions small, set tight stop losses, and prefer limit orders. Institutional investors should seek verified filings before allocating capital.

Final Thoughts

MDQK.HM stock showed a 200.00% intraday rise to €7.50 on 12 Feb 2026 during market hours on HAM, but the move came on low absolute liquidity with 35.00 shares traded. Our view is cautious: fundamentals and public disclosures remain incomplete, and the price sits far above the 50-day (€2.50) and 200-day (€2.00) averages. Meyka AI’s forecast model projects a 12-month baseline target of €9.00, implying an upside of 20.00% versus the current price €7.50. Forecasts are model-based projections and not guarantees. Short-term traders should prioritise risk controls; longer-term investors should wait for clear company updates and audited results before changing portfolio exposure. For real-time filings and the company site see the MediNavi website and track our platform page for MDQK.HM at Meyka stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.